Edgar Filing: CHINA GEWANG BIOTECHNOLOGY, INC. - Form 3

CHINA GEWANG BIOTECHNOLOGY, INC.

Form 3

February 09, 2017

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0104

0.5

washington, D.C. 2004)

Number: January 31,

OMB APPROVAL

Estimated average

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement CHINA GEWANG BIOTECHNOLOGY, INC. [CGWB] Xu Han (Month/Day/Year) 01/18/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 83 TAOJIN EAST (Check all applicable) ROAD, ROOM 401, Â YUEXIU DISTRICT _X_ 10% Owner Director (Street) Officer _Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) _X_ Form filed by One Reporting Person **GUANGZHOU** Form filed by More than One PROVINCE, Â F4Â 510623 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Ownership Beneficially Owned Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect

Common Stock 7,100,000 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

(I) (Instr. 5)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Derivative	Security:	

Edgar Filing: CHINA GEWANG BIOTECHNOLOGY, INC. - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of or Indirect

Shares (I)

(Instr. 5)

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Â

Xu Han

83 TAOJIN EAST ROAD,ROOM 401 \hat{A} \hat{A} \hat{A} \hat{A} \hat{A}

GUANGZHOU PROVINCE, F4Â 510623

Signatures

Han Xu 02/09/2017

**Signature of Date
Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Â

Remarks:

Pursuant to Note to Paragraph (a) under Rule 16a-1, 19,000,000 common shares as to which the H Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2